Clinical trial · Observational
Chemotherapy Oral Manifestations and Dental Awareness Among Parents
Oral Manifestations Of Pediatric Cancer Patients Receiving Chemotherapy And Dental Awareness Among Parents
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The prevention of oral illnesses in children and adolescents undergoing oncological treatment is critical, because oral lesions caused by this therapy significantly exacerbate the clinical condition and increase the risk of infection, as well as making it harder to perform required dental procedures when needed . "The key to success in maintaining a healthy oral cavity during therapy is patient compliance. The child and the parents should be educated regarding the possible acute side effects." Pediatric cancer patients may have a lower quality of life if they have poor dental health. Preventing and treating pre-existing oral illnesses is critical to reduce problems in these people. It is critical to raise awareness of the benefits of proper oral health so that this understanding becomes a positive attitude, reducing the discomfort of these children. The American Academy of Pediatric Dentistry (AAPD) recommends pediatric oncology/hematology that Pediatric dentists must be involved in the treatment process from the moment cancer is diagnosed. This should be carried out by having a preventive and dental care plan developed based on the patient's needs before any cancer treatment is initiated. The aim of the study is primarily to report oral complications and manifestations during chemotherapy treatment in pediatric cancer patients and raise the awareness of their parents on these manifestations thus proper interventions can be carried out to prevent more serious problems.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy Effect | — | UNRESOLVED | — |
| Mucositis Oral | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The assessment of the prevalence of oral adverse events induced by chemotherapy in pediatric cancer patients .
- timeFrame
- Baseline
- description
- Patients will be examined for oral manifestations at the first visit together with intra oral photos will be taken for the patients included in the study. Voice ,swallow ,tongue, saliva, mucous membrane\*\*, gingiva ,teeth will be measured by Oral Assessment Guide by the principal investigator . \*\*If oral mucositis is present it will be staged according to the World Health Organization Scale (WHO Oral Toxicity Scale) by the principal investigator.
Secondary outcomes (1)
- measure
- Assessment of dental awareness among parents of pediatric cancer patients .
- timeFrame
- Baseline
- description
- Questionnaire (structured questionnaire that is developed and validated by Gupta et al., 2016) Parents of the pediatric cancer patients participating in the study will complete the "Parental dental Awareness Questionnaire" to assess their awareness.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 1 Year
- Maximum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: * Children between the age of 1 -14years. * Children receiving chemotherapy for hematological cancer or solid tumors. * Parents who are able to understand the aim of the study and willing to participate in the study. Exclusion Criteria: * Children previously received radiotherapy on head and neck region. * Children suffering from oral cancer. * Children presented with other oral disorders such as leukoplakia.
References
Publications (1)
- DERIVEDAl-Sayed AM, El-Tawil SB, Madney Y, Yousry YM. Oral manifestations of pediatric cancer patients receiving chemotherapy and dental awareness among their parents-a cross-sectional study. BMC Oral Health. 2026 Mar 27;26(1):633. doi: 10.1186/s12903-026-07983-7. PMID 41896812